Literature DB >> 25964861

Atypical chemokine receptor 2: a brake against Kaposi's sarcoma aggressiveness.

Raffaella Bonecchi1, Benedetta Savino1, Nicoletta Caronni1, Giuseppe Celesti2, Alberto Mantovani1, Massimo Locati1.   

Abstract

Inflammatory chemokines are instrumental players in cancer-related inflammation contributing to numerous steps during tumor progression. In Kaposi's sarcoma, we have found that downregulation of the atypical chemokine receptor 2 (ACKR2) by the KRAS/BRAF/ERK pathway profoundly affects the tumor microenvironment, unleashing accumulation of tumor-associated macrophages that sustains tumor growth. This discovery extends our understanding on the role of inflammatory chemokines in tumor biology and provides rationale for their therapeutic targeting.

Entities:  

Keywords:  Kaposi's sarcoma; atypical chemokine receptors; chemokines; inflammation and cancer; macrophages

Year:  2015        PMID： 25964861      PMCID： PMC4353167          DOI： 10.4161/21624011.2014.955337

Source DB:  PubMed          Journal:  Oncoimmunology        ISSN： 2162-4011            Impact factor:   8.110


  10 in total

1.  The beta-chemokine receptor D6 is expressed by lymphatic endothelium and a subset of vascular tumors.

Authors:  R J Nibbs; E Kriehuber; P D Ponath; D Parent; S Qin; J D Campbell; A Henderson; D Kerjaschki; D Maurer; G J Graham; A Rot
Journal:  Am J Pathol       Date:  2001-03       Impact factor: 4.307

Review 2.  Tuning inflammation and immunity by chemokine sequestration: decoys and more.

Authors:  Alberto Mantovani; Raffaella Bonecchi; Massimo Locati
Journal:  Nat Rev Immunol       Date:  2006-12       Impact factor: 53.106

3.  ERK-dependent downregulation of the atypical chemokine receptor D6 drives tumor aggressiveness in Kaposi sarcoma.

Authors:  Benedetta Savino; Nicoletta Caronni; Achille Anselmo; Fabio Pasqualini; Elena Monica Borroni; Gianluca Basso; Giuseppe Celesti; Luigi Laghi; Athanasia Tourlaki; Vinicio Boneschi; Lucia Brambilla; Manuela Nebuloni; Gianluca Vago; Alberto Mantovani; Massimo Locati; Raffaella Bonecchi
Journal:  Cancer Immunol Res       Date:  2014-04-02       Impact factor: 11.151

4.  Control of murine Ly6C(high) monocyte traffic and immunosuppressive activities by atypical chemokine receptor D6.

Authors:  Benedetta Savino; Marina G Castor; Nicoletta Caronni; Adelaida Sarukhan; Achille Anselmo; Chiara Buracchi; Federica Benvenuti; Vanessa Pinho; Mauro M Teixeira; Alberto Mantovani; Massimo Locati; Raffaella Bonecchi
Journal:  Blood       Date:  2012-04-13       Impact factor: 22.113

Review 5.  The chemokine system in cancer biology and therapy.

Authors:  Alberto Mantovani; Benedetta Savino; Massimo Locati; Luca Zammataro; Paola Allavena; Raffaella Bonecchi
Journal:  Cytokine Growth Factor Rev       Date:  2009-12-08       Impact factor: 7.638

6.  Profiling of transcripts and proteins modulated by K-ras oncogene in the lung tissues of K-ras transgenic mice by omics approaches.

Authors:  Sojung Lee; Jungwoo Kang; Minchul Cho; Eunhee Seo; Heesook Choi; Eunjin Kim; Junghee Kim; Heejong Kim; Gum Yong Kang; Kwang Pyo Kim; Young-Ho Park; Dae-Yeul Yu; Young Na Yum; Sue-Nie Park; Do-Young Yoon
Journal:  Int J Oncol       Date:  2009-01       Impact factor: 5.650

7.  The lymphatic system controls intestinal inflammation and inflammation-associated Colon Cancer through the chemokine decoy receptor D6.

Authors:  Stefania Vetrano; Elena M Borroni; Adelaida Sarukhan; Benedetta Savino; Raffaella Bonecchi; Carmen Correale; Vincenzo Arena; Massimo Fantini; Massimo Roncalli; Alberto Malesci; Alberto Mantovani; Massimo Locati; Silvio Danese
Journal:  Gut       Date:  2009-10-20       Impact factor: 23.059

Review 8.  Cancer-related inflammation.

Authors:  Alberto Mantovani; Paola Allavena; Antonio Sica; Frances Balkwill
Journal:  Nature       Date:  2008-07-24       Impact factor: 49.962

9.  The atypical chemokine receptor D6 suppresses the development of chemically induced skin tumors.

Authors:  Robert J B Nibbs; Derek S Gilchrist; Vicky King; Antonio Ferra; Steve Forrow; Keith D Hunter; Gerard J Graham
Journal:  J Clin Invest       Date:  2007-07       Impact factor: 14.808

Review 10.  Hallmarks of cancer: the next generation.

Authors:  Douglas Hanahan; Robert A Weinberg
Journal:  Cell       Date:  2011-03-04       Impact factor: 41.582
  10 in total
  3 in total

Review 1.  The multifarious roles of the chemokine CXCL14 in cancer progression and immune responses.

Authors:  Joseph A Westrich; Daniel W Vermeer; Paul L Colbert; William C Spanos; Dohun Pyeon
Journal:  Mol Carcinog       Date:  2020-03-24       Impact factor: 4.784

Review 2.  ACKR2: An Atypical Chemokine Receptor Regulating Lymphatic Biology.

Authors:  Ornella Bonavita; Valeria Mollica Poeta; Elisa Setten; Matteo Massara; Raffaella Bonecchi
Journal:  Front Immunol       Date:  2017-01-11       Impact factor: 7.561

3.  ACKR2 in hematopoietic precursors as a checkpoint of neutrophil release and anti-metastatic activity.

Authors:  Matteo Massara; Ornella Bonavita; Benedetta Savino; Nicoletta Caronni; Valeria Mollica Poeta; Marina Sironi; Elisa Setten; Camilla Recordati; Laura Crisafulli; Francesca Ficara; Alberto Mantovani; Massimo Locati; Raffaella Bonecchi
Journal:  Nat Commun       Date:  2018-02-14       Impact factor: 14.919
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.